AR signaling in humanmalignancies: Prostate cancer and beyond

Research output: Contribution to journalEditorial

Abstract

The notion that androgens and androgen receptor (AR) signaling are the hallmarks of prostate cancer oncogenesis and disease progression is generally well accepted. What is more poorly understood is the role of AR signaling in other human malignancies. This special issue of Cancers initially reviews the role of AR in advanced prostate cancer, and then explores the potential importance of AR signaling in other epithelial malignancies. The first few articles focus on the use of novel AR-targeting therapies in castration-resistant prostate cancer and the mechanisms of resistance to novel antiandrogens, and they also outline the interaction between AR and other cellular pathways, including PI3 kinase signaling, transcriptional regulation, angiogenesis, stromal factors, Wnt signaling, and epigenetic regulation in prostate cancer. The next several articles review the possible role of androgens and AR signaling in breast cancer, bladder cancer, salivary gland cancer, and hepatocellular carcinoma, as well as the potential treatment implications of using antiandrogen therapies in these non-prostatic malignancies.

Original languageEnglish (US)
Article number22
JournalCancers
Volume10
Issue number1
DOIs
StatePublished - Jan 18 2018

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Salivary Gland Neoplasms
Androgen Antagonists
Urinary Bladder Neoplasms
Androgens
Neoplasms
Angiogenesis Inducing Agents
Castration
Phosphatidylinositol 3-Kinases
Epigenomics
Disease Progression
Hepatocellular Carcinoma
Carcinogenesis
Breast Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

AR signaling in humanmalignancies : Prostate cancer and beyond. / Antonarakis, Emmanuel.

In: Cancers, Vol. 10, No. 1, 22, 18.01.2018.

Research output: Contribution to journalEditorial

@article{a24e4c55311643398234c791db28c763,
title = "AR signaling in humanmalignancies: Prostate cancer and beyond",
abstract = "The notion that androgens and androgen receptor (AR) signaling are the hallmarks of prostate cancer oncogenesis and disease progression is generally well accepted. What is more poorly understood is the role of AR signaling in other human malignancies. This special issue of Cancers initially reviews the role of AR in advanced prostate cancer, and then explores the potential importance of AR signaling in other epithelial malignancies. The first few articles focus on the use of novel AR-targeting therapies in castration-resistant prostate cancer and the mechanisms of resistance to novel antiandrogens, and they also outline the interaction between AR and other cellular pathways, including PI3 kinase signaling, transcriptional regulation, angiogenesis, stromal factors, Wnt signaling, and epigenetic regulation in prostate cancer. The next several articles review the possible role of androgens and AR signaling in breast cancer, bladder cancer, salivary gland cancer, and hepatocellular carcinoma, as well as the potential treatment implications of using antiandrogen therapies in these non-prostatic malignancies.",
author = "Emmanuel Antonarakis",
year = "2018",
month = "1",
day = "18",
doi = "10.3390/cancers10010022",
language = "English (US)",
volume = "10",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - AR signaling in humanmalignancies

T2 - Prostate cancer and beyond

AU - Antonarakis, Emmanuel

PY - 2018/1/18

Y1 - 2018/1/18

N2 - The notion that androgens and androgen receptor (AR) signaling are the hallmarks of prostate cancer oncogenesis and disease progression is generally well accepted. What is more poorly understood is the role of AR signaling in other human malignancies. This special issue of Cancers initially reviews the role of AR in advanced prostate cancer, and then explores the potential importance of AR signaling in other epithelial malignancies. The first few articles focus on the use of novel AR-targeting therapies in castration-resistant prostate cancer and the mechanisms of resistance to novel antiandrogens, and they also outline the interaction between AR and other cellular pathways, including PI3 kinase signaling, transcriptional regulation, angiogenesis, stromal factors, Wnt signaling, and epigenetic regulation in prostate cancer. The next several articles review the possible role of androgens and AR signaling in breast cancer, bladder cancer, salivary gland cancer, and hepatocellular carcinoma, as well as the potential treatment implications of using antiandrogen therapies in these non-prostatic malignancies.

AB - The notion that androgens and androgen receptor (AR) signaling are the hallmarks of prostate cancer oncogenesis and disease progression is generally well accepted. What is more poorly understood is the role of AR signaling in other human malignancies. This special issue of Cancers initially reviews the role of AR in advanced prostate cancer, and then explores the potential importance of AR signaling in other epithelial malignancies. The first few articles focus on the use of novel AR-targeting therapies in castration-resistant prostate cancer and the mechanisms of resistance to novel antiandrogens, and they also outline the interaction between AR and other cellular pathways, including PI3 kinase signaling, transcriptional regulation, angiogenesis, stromal factors, Wnt signaling, and epigenetic regulation in prostate cancer. The next several articles review the possible role of androgens and AR signaling in breast cancer, bladder cancer, salivary gland cancer, and hepatocellular carcinoma, as well as the potential treatment implications of using antiandrogen therapies in these non-prostatic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=85041348326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041348326&partnerID=8YFLogxK

U2 - 10.3390/cancers10010022

DO - 10.3390/cancers10010022

M3 - Editorial

C2 - 29346310

AN - SCOPUS:85041348326

VL - 10

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 1

M1 - 22

ER -